224 related articles for article (PubMed ID: 19487811)
1. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy.
Abuzeid WM; Jiang X; Shi G; Wang H; Paulson D; Araki K; Jungreis D; Carney J; O'Malley BW; Li D
J Clin Invest; 2009 Jul; 119(7):1974-85. PubMed ID: 19487811
[TBL] [Abstract][Full Text] [Related]
2. Targeting Rad50 sensitizes human nasopharyngeal carcinoma cells to radiotherapy.
Chang L; Huang J; Wang K; Li J; Yan R; Zhu L; Ye J; Wu X; Zhuang S; Li D; Zhang G
BMC Cancer; 2016 Mar; 16():190. PubMed ID: 26951044
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
[TBL] [Abstract][Full Text] [Related]
4. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D
Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139
[TBL] [Abstract][Full Text] [Related]
5. Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer.
Araki K; Yamashita T; Reddy N; Wang H; Abuzeid WM; Khan K; O'Malley BW; Li D
Br J Cancer; 2010 Dec; 103(12):1822-30. PubMed ID: 21063405
[TBL] [Abstract][Full Text] [Related]
6. Head and neck squamous cell carcinoma targeted chemosensitization.
Figures MR; Wobb J; Araki K; Liu T; Xu L; Zhu H; O'Malley BW; Li D
Otolaryngol Head Neck Surg; 2009 Aug; 141(2):177-83. PubMed ID: 19643248
[TBL] [Abstract][Full Text] [Related]
7. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.
Bartkova J; Tommiska J; Oplustilova L; Aaltonen K; Tamminen A; Heikkinen T; Mistrik M; Aittomäki K; Blomqvist C; Heikkilä P; Lukas J; Nevanlinna H; Bartek J
Mol Oncol; 2008 Dec; 2(4):296-316. PubMed ID: 19383352
[TBL] [Abstract][Full Text] [Related]
8. Deletion of NAD(P)H:quinone oxidoreductase 1 represses Mre11-Rad50-Nbs1 complex protein expression in cisplatin-induced nephrotoxicity.
Kim YJ; Kim TW; Park SR; Kim HT; Jung DY; Ryu SY; Jung JY
Toxicol Lett; 2016 Jan; 243():22-30. PubMed ID: 26723870
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced cell death increases the degradation of the MRE11-RAD50-NBS1 complex through the autophagy/lysosomal pathway.
Belmonte-Fernández A; Herrero-Ruíz J; Galindo-Moreno M; Limón-Mortés MC; Mora-Santos M; Sáez C; Japón MÁ; Tortolero M; Romero F
Cell Death Differ; 2023 Feb; 30(2):488-499. PubMed ID: 36477079
[TBL] [Abstract][Full Text] [Related]
10. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer.
Tran HM; Shi G; Li G; Carney JP; O'Malley B; Li D
Otolaryngol Head Neck Surg; 2004 Oct; 131(4):477-84. PubMed ID: 15467621
[TBL] [Abstract][Full Text] [Related]
11. β-Lapachone enhances Mre11-Rad50-Nbs1 complex expression in cisplatin-induced nephrotoxicity.
Kim TW; Kim YJ; Kim HT; Park SR; Jung JY
Pharmacol Rep; 2016 Feb; 68(1):27-31. PubMed ID: 26721347
[TBL] [Abstract][Full Text] [Related]
12. Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.
Folk WP; Kumari A; Iwasaki T; Pyndiah S; Johnson JC; Cassimere EK; Abdulovic-Cui AL; Sakamuro D
J Biol Chem; 2019 Apr; 294(14):5700-5719. PubMed ID: 30733337
[TBL] [Abstract][Full Text] [Related]
13. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres.
Zhong ZH; Jiang WQ; Cesare AJ; Neumann AA; Wadhwa R; Reddel RR
J Biol Chem; 2007 Oct; 282(40):29314-22. PubMed ID: 17693401
[TBL] [Abstract][Full Text] [Related]
14. Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.
Berkel C; Cacan E
Biochem Biophys Res Commun; 2021 Sep; 570():74-81. PubMed ID: 34273621
[TBL] [Abstract][Full Text] [Related]
15. RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy.
Flores-Pérez A; Rafaelli LE; Ramírez-Torres N; Aréchaga-Ocampo E; Frías S; Sánchez S; Marchat LA; Hidalgo-Miranda A; Quintanar-Jurado V; Rodríguez-Cuevas S; Bautista-Piña V; Carlos-Reyes A; López-Camarillo C
Cancer Biol Ther; 2014 Jun; 15(6):777-88. PubMed ID: 24642965
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of FoxM1 sensitizes nasopharyngeal carcinoma cells to cisplatin via inhibition of MRN-ATM-mediated DNA repair.
Li D; Ye L; Lei Y; Wan J; Chen H
BMB Rep; 2019 Mar; 52(3):208-213. PubMed ID: 30638177
[TBL] [Abstract][Full Text] [Related]
17. MRN and the race to the break.
Rupnik A; Lowndes NF; Grenon M
Chromosoma; 2010 Apr; 119(2):115-35. PubMed ID: 19862546
[TBL] [Abstract][Full Text] [Related]
18. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma.
Adhim Z; Lin X; Huang W; Morishita N; Nakamura T; Yasui H; Otsuki N; Shigemura K; Fujisawa M; Nibu K; Shirakawa T
Cancer Gene Ther; 2012 Feb; 19(2):144-52. PubMed ID: 22116375
[TBL] [Abstract][Full Text] [Related]
19. A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner.
Wen Q; Scorah J; Phear G; Rodgers G; Rodgers S; Meuth M
Mol Biol Cell; 2008 Apr; 19(4):1693-705. PubMed ID: 18256278
[TBL] [Abstract][Full Text] [Related]
20. Enhanced DNA damage response through RAD50 in triple negative breast cancer resistant and cancer stem-like cells contributes to chemoresistance.
Abad E; Civit L; Potesil D; Zdrahal Z; Lyakhovich A
FEBS J; 2021 Apr; 288(7):2184-2202. PubMed ID: 33090711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
